Table 3 Outcomes during follow-up
Outcomes | N = 91 |
|---|---|
Cancer | 20 (22.0) |
Breast | 8 (8.8) |
Stomach | 4 (4.4) |
Lung | 2 (2.2) |
Cervical | 1 (1.1) |
Uterus | 1 (1.1) |
Melanoma | 1 (1.1) |
Thyroid | 1 (1.1) |
Non-Hodgkin’s lymphoma | 2 (2.2) |
Nasopharyngeal | 1 (1.1) |
Gastrointestinal stromal tumors | 1 (1.1) |
Severe infections | 48 (52.7) |
Pneumonia | 15 (16.5) |
Herpes-zoster | 11 (12.1) |
Tuberculosis | 5 (5.5) |
COVID-19 | 3 (3.3) |
Other causes | 58 (63.7) |
Total episodes of infections | 92 |
Death | 9 (9.9) |
Infections | 2 (2.2) |
Neoplasia | 4 (4.4) |
Other causes | 3 (3.3) |